Skip to main content
editorial
. 2022 Jun 29;19(6):769–773. doi: 10.20892/j.issn.2095-3941.2022.0277

Figure 1.

Figure 1

Recommendations for neoadjuvant and adjuvant therapy for HER2 positive breast cancer. pCR, pathological complete remission; TCHP, taxane, carboplatin, trastuzumab and pertuzumab; THP, taxane, trastuzumab and pertuzumab; HP, trastuzumab and pertuzumab; T-DM1, trastuzumab emtansine.